
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc. is positioned for positive growth due to its innovative pipeline, particularly with icotrokinra, which has demonstrated a consistent clinical response improvement in inflammation and immunology over extended periods. The company’s drug candidate is expected to capture market share previously held by Otezla, bolstered by its leading efficacy and favorable safety profile, which could translate into substantial revenue growth within the milder disease segments. Furthermore, Protagonist's robust business development track record and anticipated momentum from clinical catalysts set for 2025 suggest a promising outlook for the company's future financial performance.
Bears say
Protagonist Therapeutics Inc faces significant financial risks stemming from industry-standard uncertainties, including potential negative outcomes from ongoing clinical trials and regulatory challenges, which may hinder the development and approval of their product candidates. Additionally, the company is exposed to dilution risk due to future cash needs, compounded by pricing reform pressures that could impact revenue generation in a competitive and increasingly price-sensitive market. Despite having proprietary technology and a focused pipeline, these overarching vulnerabilities contribute to a negative outlook for the company's stock performance.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares